P2RX7 and graft versus host disease: Moreover, our group has shown that the P2X7 antagonist Brilliant Blue G (BBG) (50 mg/kg) administered i.p. daily on Days 0–10 post-human PBMC injection can also reduce GVHD development in these mice [23].